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ABSTRACT 
Objective	
The	majority	of	patients	with	supratentorial	diffuse	grade	II	glioma	present	with	seizures,	which	
adversely	affect	quality	of	life.	The	exact	mechanism	of	epileptogenesis	is	unknown	and	the	
influence	of	tumour	characteristics,	radiological	and	histological,	are	not	well	studied,	particularly	
following	the	introduction	of	molecular	genetics	in	the	2016	WHO	reclassification	of	gliomas.		We	
sought	to	define	predictors	of	seizure	development	and	outcome	in	low	grade	glioma.	
Patients	and	Methods		
A	retrospective	review	of	patients	who	underwent	resection	of	a	supratentorial	grade	II	glioma	in	a	
single	institution.		All	patients	underwent	surgery	at	initial	presentation	with	the	aim	of	maximal	safe	
resection.		Presenting	symptoms	and	radiological	variables	were	recorded,	including	eloquent	
location,	cortical	involvement,	tumour	margins	and	tumour	volume.		Extent	of	resection	(EOR),	
surgery	type	(awake	vs	asleep)	and	seizure	outcome	were	analysed.		Using	molecular	genetics	data	
the	original	histology	was	reclassified	according	to	the	2016	WHO	update.		
Results	
63	patients	were	included,	45	(71%)	presented	with	seizures.		36	(57%)	had	oligodendroglioma	and	
27	astrocytoma.		IDH-1	mutation	was	present	in	53	(84%).		18	(29%)	had	tumour	in	an	eloquent	
location.		33	(73%)	were	Engel	class	I	following	surgery	at	median	follow	up	of	43	months.		6	patients	
were	Engel	II,	6	class	III.	Complete	and	near	total	resection	were	associated	with	improved	Engel	
class	compared	to	subtotal	resection.		No	factors	such	as	age,	tumour	location,	tumour	margins	or	
tumour	molecular	genetics	(including	IDH-1	mutation)	predicted	better	seizure	outcome.		Updated	
histological	subtype	did	not	predict	the	presence	of	seizures	at	initial	diagnosis,	only	tumour	
heterogeneousity	on	initial	MRI	(p=0.043).		More	patients	who	underwent	awake	craniotomy	with	
intraoperative	mapping	were	Engel	class	1	post-operatively	than	those	operated	under	general	
anaesthetic	(84%	vs	65%).		Tumour	volume	at	presentation	did	not	correlate	with	seizure	outcome	
but	impacts	on	the	EOR.				
Conclusion	
Seizure	outcome	is	directly	related	to	EOR	in	low	grade	glioma,	which	can	be	predicted	by	the	initial	
tumour	volume.		Tumour	histological	subtype,	including	updated	molecular	genetic	classification	did	
not	predict	seizure	development	or	outcome	in	this	series.		The	use	of	awake	craniotomy	results	in	
greater	EOR	and	improved	Engel	Class	following	surgery.	
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1.  Objective 
World	Health	Organisation	(WHO)	grade	II	gliomas	(low-grade	gliomas;	LGGs)	are	a	heterogeneous	
group	of	primary	central	nervous	system	(CNS)	tumours	arising	from	glial	cells	(1).	LGGs	are	shown	
to	exhibit	an	average	growth	rate	of	around	4mm/year	and	will	eventually	undergo	malignant	
transformation	(2,3).	The	recent	WHO	classification	system	of	LGGs	classifies	them	as	either	
astrocytoma	or	oligodendroglioma,	emphasising	the	use	of	molecular	genetics	to	distinguish	tumour	
type.	Previously,	an	additional	classification	of	oligoastrocytoma	existed,	however,	this	has	been	
removed	in	the	recent	updated	classification	system	(4).		
Most	patients	with	LGGs	present	within	the	third	or	fourth	decades	of	life	with	an	overall	incidence	
of	0.63-1.8/100,000	adults	per	year	(5,6).	They	are	highly	epileptogenic	tumours	with	60-88%	of	
patients	presenting	with	seizure	activity	(7–10).	The	exact	mechanisms	of	tumour	epileptogenesis	
are	not	fully	understood	but	multiple	factors	appear	to	play	roles.	Potential	factors	predominantly	
involve	peritumoural	changes	in	metabolism,	perfusion,	electrolytes	and	enzyme	activity.	(11).	For	
example,	IDH	mutations	occur	in	up	to	80%	of	LGGs	and	are	believed	to	contribute	to	
epileptogenesis	by	causing	production	of	a	structurally	similar	compound	to	glutamate	and	thus	
activating	NMDA	receptors	(11).		
Previously,	management	of	LGGs	involved	a	‘watch-and-wait’	approach.	However,	there	has	been	a	
recent	shift	towards	earlier	and	more	aggressive	management	due	to	the	inevitable	malignant	
transformation	(2,12).	A	range	of	studies	have	shown	more	favourable	outcomes	with	early	surgical	
resection,	particularly	with	a	greater	extent	of	resection	(EOR)	(13,14).	In	terms	of	seizure	outcome,	
studies	have	shown	seizure	freedom	in	up	to	65-81%	of	patients	post-resection,	but	the	exact	
prognostic	factors	that	influence	seizure	outcome	are	not	yet	fully	understood	(6,8,9,15).		
This	study	aimed	to	assess	seizure	outcome	in	a	series	of	operated	LGG	patients	and	identify	any	
pre-	or	post-operative	predictors	which	may	influence	eventual	seizure	outcome,	including	tumour	
type	based	on	the	up-to-date	molecular	genetic	analysis	of	the	2016	WHO	classification	update.	
	
	
	
	
	
	
	
	
	
	
2.  Patients and Methods 
2.1	Patient	Population	
A	total	of	63	patients	with	operated	supratentorial	grade	II	gliomas	were	included	in	this	study,	
consisting	of	36	oligodendrogliomas	and	27	astrocytomas	(according	to	WHO	2016	classification).	All	
patients	underwent	surgical	resection	of	their	tumour	at	initial	presentation,	between	May	2011	to	
December	2016	in	a	single	institution.	Those	patients	that	only	underwent	biopsy	were	excluded	
from	the	study.		Additionally,	all	cases	with	tumours	classified	grade	II/III	were	excluded.			
Clinical	records	were	retrospectively	analysed	for	symptoms	at	presentation,	seizure	type,	type	of	
resection	(awake	vs	asleep),	adjuvant	treatments,	seizure	outcome	(Engel	class;	table	1)	and	the	
presence	and	grade	of	tumour	recurrence.	Seizure	outcome	was	assessed	at	3,	6	and	12	months	
post-operatively	and	at	most	recent	clinic	follow	up	(median	follow	up	time	of	40	months).		Tissue	
samples	were	analysed	for	all	but	2	patients	in	terms	of	their	immunohistochemistry	(IHC)	and	
molecular	genetics	and	tumours	were	reclassified	according	to	the	2016	system	retrospectively.	
Reclassification	was	performed	on	the	basis	that	a	tumour	with	an	IDH	mutation	plus	1p19q	
mutation	is	an	oligodendroglioma	and	an	IDH	mutation	plus	ATRX	mutation	is	an	astrocytoma.		All	
tissue	samples	in	our	institution	have	had	IDH1	mutation	IHC	and	molecular	genetics	performed	
since	2011	enabling	retrospective	reclassification	in	the	majority	of	cases.		
	
Engel	class	 		
I	 Seizure	free	without	aura;	seizures	only	on	withdrawal	of	anti-epileptic	drug	(AED)	
II	 Rare	disabling	seizures	
III	 Worthwhile	improvement	
IV		 No	worthwhile	improvement/worsening	seizures	
2.2	MRI	Analysis	
The	recorded	MRI	information	included	laterality	(left	or	right	hemisphere),	location	(frontal,	
temporal,	parietal,	insular	or	a	combination),	presence	of	cortical	involvement,	mass	effect	and	
location	in	an	eloquent	region.	Tumours	were	also	described	with	relation	to	their	borders	(distinct	
vs	indistinct)	and	tumour	signal	on	MRI	(homogenous	vs	heterogenous).	Tumour	size	was	analysed	
using	the	widest	diameter	in	three	directions	and	tumour	volume	calculated	(ellipsoid	method	
volume=D1xD2xD3/2).	EOR	was	described	as	complete,	near-total	(>90%)	and	subtotal	(<90%),	
based	on	immediate	post-
A	 B	
Table	1	–	Overview	of	Engel	classification	system;	from	Tanriverdi	et	al.	16.	
C	
Figure	1	–	Axial	MRI	images	from	two	patients.	A)	Shows	an	example	of	a	heterogenous	glioma	with	
indistinct	borders	on	T2.	B)	shows	an	example	of	a	homogenous	LGG	with	distinct	borders.	C)	Post-
operative	surgical	cavity	on	FLAIR	after	resection	of	tumour	B.	
operative	MRI.	
	
Statistical	analysis	was	performed	using	SPSS,	Version	24	IBM	Corp,	Armonk	NY.		Univariate	analysis	
was	performed	using	χ2	and	Fishers	exact	test	where	appropriate	and	paired	t	tests	for	continuous	
variables.	A	P	value	of	<0.05	was	considered	significant.	
3.  Results 
Our	cohort	included	a	total	of	63	patients,	43	male	and	20	female,	with	a	median	age	of	34	years.	36	
patients	had	oligodendogliomas	and	27	had	astrocytomas	with	30	being	located	in	the	right	
hemisphere	and	33	in	the	left	hemisphere.	The	key	clinical	and	demographic	characteristics	are	
displayed	in	table	2.	
Parameter	 Total	number	of	cases	
Total	patients	 63	
Males	 43	(68%)	
Females	 20	(32%)	
Median	age	 34	
Median	follow	up	time	 40	months	
Deceased	patients	 4	
Median	time	to	death	 29	months	(range	11-44)	
Tumour	 	
Oligodendroglioma	 36	(57%)	
Astrocytoma	 27	(43%)	
IDH-1	mutation	 53	(84%)	
Right	hemisphere	 30	(48%)	
Left	hemisphere	 33	(52%)	
Eloquent	region	(+	SMA)	 18	(29%)			
Non-eloquent	 45	(71%)	
Seizures	 	
Total	seizures	 45	(71%)	
GTC	 17	(38%)	
Partial	 15	(33%)	
Combined	GTC	and	partial		 13	(29%)	
Surgery	 	
Awake	 25	
General	anaesthetic	(GA)	 38	
	
	The	main	presenting	complaint	was	seizure	in	45	(71%)	patients,	of	which	17	(38%)	were	
generalised	tonic-clonic	seizures	(GTC),	15	(33%)	were	focal	seizures	and	13	(29%)	had	a	combination	
of	focal	and	generalised.	Other	presenting	symptoms	included	headache	(3%),	focal	neurological	
deficit	(5%),	a	combination	of	the	two	(11%)	or	were	incidental	findings	(5%).	There	were	53	patients	
with	IDH-1	mutations	present	(84%)	of	which	41	presented	with	seizures	(77%).	Four	
oligodendrogliomas	and	four	astrocytomas	did	not	have	IDH-1	mutations	present	and	thus	classify	as	
Table	2	–	Summary	of	overall	patient	parameters.	Tumours	situated	within	the	supplementary	
motor	area	(SMA)	have	been	included	in	the	eloquent	group.	
oligodendroglioma,	NOS,	and	astrocytoma,	NOS,	respectively.	Two	patients	with	morphological	
astrocytomas	did	not	have	molecular	genetics	available.	
	
3.1	Patients	Presenting	with	Seizures	
Seizure	outcome	was	assessed	using	the	Engel	classification	system	(table	1).	33	out	of	45	patients	
(73%)	presenting	with	seizures	were	Engel	class	I	post-operatively	at	a	median	follow	up	of	43	
months.	All	remaining	patients	gained	some	benefit	from	resection	(6	patients	were	Engel	class	II,	6	
were	class	III).	Seizure	outcome	was	assessed	at	3,	6	and	12	months	post-operatively	as	well	as	up	to	
most	recent	status.	41	patients	were	Engel	class	I	at	3	months	(91%),	39	at	6	months	(87%)	and	36	at	
12	months	(80%).	No	patients	were	Engel	class	IV.	Median	and	mean	times	to	seizure	recurrence	
were	10.5	months	and	17.8	months	respectively	(range	3-48	months).	Of	the	12	patients	with	
seizure	recurrence,	6	(50%)	had	evidence	of	tumour	recurrence	at	the	time.	Seizure	recurrence	was	
not	significantly	associated	with	tumour	recurrence	or	progression,	with	seizure	recurrence	or	new	
seizures	occurring	in	only	8	out	of	the	25	patients	(32%)	with	tumour	recurrence	in	the	series.		
We	analysed	data	for	other	variables	that	might	predict	eventual	Engel	class	after	surgery.	Greater	
EOR	tended	to	give	better	seizure	outcome,	with	complete	and	near-total	resection	resulting	in	
Engel	class	I	in	76%	and	87.5%	respectively	compared	to	62.5%	of	subtotal	resections.		Complete	
resection	is	the	strongest	predictor	of	seizure	freedom	compared	to	either	near	or	subtotal	resection	
(p=0.066).		Demographics	including	patient	age,	IDH	status	and	type	of	surgery	did	not	significantly	
predict	seizure	outcome,	but	this	may	be	related	to	the	small	sample	size	within	subgroups.	Tumour	
type	did	not	significantly	predict	seizure	outcome,	whether	using	the	2016	WHO	classification	
system	or	the	previous	system.	Based	on	the	2016	classification	system,	patients	with	
oligodendrogliomas	had	a	slightly	greater	seizure	freedom	rate	than	those	with	astrocytomas,	but	
this	is	not	significant	(79%	vs	67%;	p=0.299).	This	is	similar	to	results	based	on	the	previous	
classification	system,	where	88%	of	oligodendrogliomas,	61%	of	astrocytomas	and	60%	of	
oligoastrocytomas	were	seizure	free.	More	patients	who	underwent	an	awake	craniotomy	with	
intra-operative	functional	mapping	were	Engel	class	I	post-operatively	compared	to	those	under	GA	
but	this	was	non-significant	(84%	vs	65%;	p=0.80).	There	were	no	radiological	variables	that	
significantly	predicted	seizure	outcome,	including	eloquent	location,	cortical	involvement,	border	
distinction,	mass	effect	or	tumour	signal.	
	
Figure	3	-	Seizure	outcomes	using	Engel	classification	system	based	on	operative	factors	-	EOR	
(complete,	near-total	or	sub-total)	and	type	of	surgery	(awake	vs	GA).	Blue	bars	indicate	Engel	
class	I,	orange	bars	indicate	Engel	class	II	or	above.	Data	only	used	from	patients	presenting	with	
seizures	(total	n=45).	Individual	bar	totals	are	the	total	number	of	patients	presenting	with	
seizures	within	each	category.	
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Figure	2	–	Seizure	outcomes	using	Engel	classification	system	based	on	pre-operative	factors	
(tumour	type,	seizure	type	and	tumour	location	as	either	eloquent	(including	SMA)	or	non-
eloquent.	Blue	bars	indicate	Engel	class	I,	orange	bars	indicate	Engel	class	II	or	above.	Data	only	
used	from	patients	presenting	with	seizures	(n=45).	Individual	bar	totals	are	the	total	number	of	
patients	presenting	with	seizures	within	each	category.	
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We	also	analysed	data	to	identify	if	any	factors	predicted	whether	seizures	were	the	presenting	
symptom.	The	only	variable	to	significantly	predict	seizures	as	a	presenting	symptom	was	tumour	
signal	on	MRI,	where	81%	of	tumours	with	a	heterogeneous	appearance	produced	seizures	
compared	to	58%	of	homogenous	tumours	(p=0.043).	Other	demographics	including	age,	IDH	status	
and	tumour	volume	and	radiological	variables	of	eloquent	location,	cortical	involvement,	mass	effect	
and	border	distinction	did	not	significantly	predict	whether	seizures	were	the	presenting	symptom.	
We	tried	to	identify	whether	any	variables	correlated	with	tumour	type	based	on	the	2016	WHO	
classification	system.	More	oligodendrogliomas	had	indistinct	borders	(59%)	compared	to	
astrocytomas	(35%),	p=0.05.	No	other	factors,	including	seizures	as	a	presenting	symptoms,	IDH	
status,	tumour	recurrence	and	tumour	signal	on	MRI,	significantly	correlated	with	reclassified	
tumour	type.	
Tumour	volume	at	presentation	did	not	correlate	with	eventual	seizure	outcome	(p=0.70).		However,	
EOR	was	significantly	greater	in	tumours	with	smaller	volumes.	The	mean	tumour	volume	in	patients	
who	underwent	complete	or	near-total	resection	was	23.8	cm3	compared	to	54.9	cm3	in	those	who	
underwent	subtotal	resection	(p=<0.01).	Tumours	in	eloquent	locations	had	significantly	smaller	
volumes	than	those	in	non-eloquent	locations,	with	mean	volumes	of	22.0	cm3	and	37.7	cm3	
respectively	(p=0.035).		
3.2	Patients	with	no	seizures	at	presentation	
Parameter		 Number	of	cases			
18	patients	did	not	present	with	seizures	and	their	key	parameters	are	outlined	in	table	3.	As	
previously	stated,	the	only	variable	that	significantly	predicted	seizures	as	a	presenting	symptom	
was	heterogeneous	MRI	appearance,	with	those	with	heterogenous	tumour	signal	being	more	likely	
to	present	with	seizures,	although	this	did	not	correlate	with	a	specific	tumour	type.		Median	tumour	
size	in	patients	who	did	not	present	with	seizures	was	14.55cm3	compared	to	36.85cm3	in	those	who	
did.		
7	patients	did	eventually	develop	seizures	(6	GTC;	1	partial)	at	a	median	time	of	29	months.	Of	these	
new	cases	of	seizures,	6	were	oligodendrogliomas	and	1	was	astrocytoma.	Only	one	new	seizure	
case	was	associated	with	radiological	tumour	progression	recurrence	of	an	oligodendroglioma	which	
had	undergone	subtotal	resection.	There	were	no	factors	that	predict	which	patients	would	go	on	to	
develop	seizures.	EOR	was	complete	or	near	total	in	5	patients	with	new	seizures	(71%)	compared	to	
10	out	of	11	patients	who	never	had	seizures	(91%).		
3.3	Tumour	Outcome	
Tumour	recurrence	or	progression	occurred	in	25	(40%)	patients	in	the	series,	with	median	time	to	
recurrence	of	22	months.	Of	these,	fourteen	recurred	as	grade	II,	eight	as	grade	III	and	three	as	
grade	IV.	
In	patients	presenting	with	seizures	(n=20)	the	median	time	to	recurrence	was	22.5	months	vs	21	
months	in	those	who	did	not	present	with	seizures	(n=5)	Figure	1.	Table	4	shows	the	EOR	and	
tumour	grade	at	recurrence	for	the	25	patients	who	progressed.	In	this	cohort,	patients	who	
underwent	subtotal	resection	were	more	likely	to	have	progression	than	those	with	complete	or	
near-total	resection,	with	progression	occurring	in	52%	of	subtotal	resections	and	27%	of	
complete/near-total	resections	(p=0.044).	Importantly,	of	tumours	recurring	as	grade	III	or	IV,	only	
one	out	of	nine	patients	had	undergone	complete	resection	(11%).	
Total	patients		 18		
Tumour	type	 		
Oligodendroglioma	 12	(67%)	
Astrocytoma	 6	(33%)	
IDH	mutation	 	
Present	 16	(89%)	
Absent	 2	(11%)	
Development	of	Seizures	 7	(39%)	
GTC	 6	(86%)*	
Partial	 1	(14%)*	
EOR	and	MRI	Characteristics	 	
Complete	 9	(50%)	
Near-total	 6	(33%)	
Sub-total	 3	(17%)	
Eloquent	 5	(28%)	
Non-eloquent	 13	(72%)	
Cortical	involvement	 7	(39%)	
Mass	Effect	 6	(33%)	
Distinct	borders	 10	(56%)	
Homogenous	appearance	 11	(61%)	
Grade	at	Recurrence	 Complete	
resection	
Near-
total	
resection	
Subtotal	
resection	
Table	3	–	Parameters	for	patients	whom	did	not	presenting	with	seizures.	*	indicates	percentage	
of	seizure	cases	
Table	4	–	comparison	of	EOR	rates	in	different	grades	of	tumour	recurrence	
	Larger	tumours	were	also	more	likely	to	recur.	The	mean	tumour	volume	in	patients	who	had	
recurrence	was	44.2	cm3	compared	to	26.0	cm3	in	patients	with	no	recurrence	(p=0.008).	Mass	
effect	was	also	predictive	of	tumour	recurrence,	where	recurrence	occurred	in	67%	of	patients	with	
evidence	of	mass	effect	on	pre-operative	MRI,	compared	to	19%	of	those	with	no	mass	effect	
evident	(p=<0.01).	IDH	status,	type	of	surgery	and	radiological	variables	of	border	distinction,	cortical	
involvement	and	tumour	signal	did	not	significantly	predict	recurrence.	
Overall,	greater	EOR	was	generally	achieved	with	awake	craniotomy	with	13	undergoing	complete	
resection	(52%),	7	near-total	(28%)	and	only	5	sub-total	(20%).	In	comparison,	in	the	general	
anaesthesia	(GA)	group	a	complete	resection	was	achieved	in	17	patients	(45%),	near-total	in	7	
patients	(18%)	and	sub-total	in	14	patients	(37%).	However,	this	did	not	statistically	predict	seizure	
freedom	(p=0.80).	
Most	patients	were	treated	before	the	publication	of	the	RTOG	9802	study,	therefore	the	use	of	
adjuvant	treatment	was	mixed.		17	patients	received	adjuvant	therapy	after	initial	tumour	resection	
due	to	significant	residual	disease.		8	received	radiotherapy	alone,	2	received	chemotherapy	alone	
and	7	received	combined	chemo-radiotherapy.	11	(65%)	had	oligodendrogliomas,	the	remainder	had	
astrocytomas.	Of	the	patients	who	initially	presented	with	seizures	(n=45),	9	received	adjuvant	
therapy,	compared	to	8	patients	out	of	those	who	did	not	present	with	seizures	(n=18).	11	patients	
who	had	adjuvant	treatment	were	Engel	class	I	(65%).	Our	data	did	not	show	a	statistically	significant	
improvement	in	seizure	outcome	after	adjuvant	therapy	compared	to	no	adjuvant	therapy	(p=0.33).	
3.4	Outcomes	Before	and	After	the	2016	WHO	Update	
After	reclassification	there	were	36	patients	with	oligodendroglioma	and	27	with	astrocytoma.	Based	
on	the	original	histological	classification	before	the	2016	update	there	were	28	with	
oligodendroglioma,	24	with	astrocytoma,	11	with	oligoastrocytoma.	Of	the	oligoastrocytomas,	7	
were	reclassified	to	oligodendroglioma	and	4	to	astrocytoma.		
	 Total	cases	 Seizures	 Engel	I	 Engel	II+	
Before	Update	 	 	 	 	
Oligodendroglioma	 28	 18	 16	(89%)	 2	(11%)	
Astrocytoma	 24	 17	 11	(63%)	 6	(37%)	
Oligoastrocytoma	 11	 10	 6	(60%)	 4	(40%)	
	 	 	 	 	
After	Update	 	 	 	 	
Oligodendroglioma	 36	 24	 19	(79%)	 5	(21%)	
Astrocytoma	 27	 21	 14	(67%)	 7	(33%)	
II	 6	 3	 5	
II/III	 2	 	 	
III	 1	 1	 4	
III/IV	 	 	 1	
IV	 	 1	 1	
Table	5	–	Comparison	of	cases	before	and	after	reclassification	using	2016	WHO	update	
	As	shown	in	table	5,	tumours	previously	classified	as	oligoastrocytoma	were	most	likely	to	present	
with	seizures.	Oligodendrogliomas	were	also	more	likely	to	be	Engel	class	I	post-operatively,	
whereas	oligoastrocytomas	were	least	likely.	More	oligoastrocytomas	were	reclassified	as	
oligodendroglioma	than	astrocytoma,	which	may	have	affected	Engel	class	outcomes	post-update	as	
there	were	10%	fewer	oligodendroglioma	patients	Engel	class	I	after	reclassification.	However,	
seizure	outcome	was	virtually	unchanged	in	astrocytomas	before	and	after	the	update.	
In	new	cases	of	seizures,	there	was	no	change	between	pre-	and	post-updated	classification,	with	6	
cases	of	new	seizures	in	patients	with	oligodendrogliomas	and	1	with	astrocytoma.	
Tumour	recurrence	was	not	significantly	impacted	after	the	updated	classification.		25	patients	had	
tumour	recurrence,	12	of	which	were	oligodendroglioma	and	13	astrocytoma.	Before	
reclassification,	these	25	patients	were	made	up	of	9	oligodendrogliomas,	11	astrocytomas	and	5	
oligoastrocytomas.		
4.  Discussion 
The	main	outcome	of	this	study	was	to	assess	seizure	outcome	in	patients	with	LGGs	and	identify	
any	imaging,	molecular	or	operative	predictors	of	seizure	development	and	seizure	freedom	based	
on	the	2016	WHO	classification	system	(4).		
Our	result	of	73%	patients	being	Engel	class	I	post-operatively	is	in	keeping	with	other	data,	with	a	
range	of	67-81%	reported	(6,8,15,16).	The	proportion	of	our	patients	being	Engel	class	I	decreases	
with	time	post-operatively,	as	shown	by	the	seizure	freedom	rates	at	3,	6	and	12	months	post-
operatively	(91%,	87%	and	80%	respectively).		
EOR	appears	to	be	a	strong	predictor	of	seizure	freedom	(Engel	class	I)	after	resection	(8,15,17).	Our	
results	of	Engel	class	I	for	complete	(76%),	near-total	(87.5%)	and	subtotal	resection	(62.5%)	show	
preferable	seizure	outcome	with	greater	EOR.	This	is	in	keeping	with	other	literature,	for	example	Xu	
et	al.	(15)	found	an	EOR	>80%	gave	better	seizure	outcome	(Engel	class	I)	and	a	meta-analysis	
showed	80%	seizure	freedom	from	gross-total	resection	compared	to	53%	of	subtotal	resections	
(17),	again	similar	to	our	data.	Seizure	freedom	in	62.5%	of	subtotal	resections	still	shows	the	
surgical	benefit	to	seizure	outcome	even	when	a	lower	EOR	is	achieved.	The	widespread	push	
towards	maximal	early	resection	appears	to	provide	improved	seizure	outcomes.	In	fact,	
“supratotal”	resection,	whereby	the	tumour	is	removed	along	with	a	margin	visible	on	FLAIR-
weighted	MRI,	has	been	shown	to	produce	favourable	seizure	outcomes	as	well	as	a	significant	
reduction	in	the	risk	of	malignant	transformation	(14).		This	is	reflected	in	the	fact	that	in	this	study	
EOR	was	also	a	significant	predictor	of	tumour	recurrence	as	tumours	were	significantly	more	likely	
to	recur	with	an	incomplete	EOR	compared	to	near-total	or	complete,	despite	adjuvant	therapy.	
Adjuvant	therapy	did	not	appear	to	give	favourable	seizure	outcomes	in	this	cohort	(p=0.33)	which	
may	be	due	to	the	fact	that	adjuvant	therapy	tended	to	be	used	in	those	with	significant	residual	
disease	(incomplete	EOR)	which	is	a	negative	prognostic	factor	in	itself.		
Our	data	also	show	that	seizure	outcome	is	improved	when	resection	is	performed	as	awake	
craniotomy	with	intra-operative	functional	mapping	compared	to	under	GA	(84%	Engel	class	I	vs	
65%).	This	may	be	due	to	an	overall	greater	EOR	in	those	operated	awake	compared	to	those	
operated	under	GA.	Of	the	19	patients	who	underwent	awake	craniotomy	and	resection,	74%	had	
complete	or	near-total	resection	compared	to	58%	of	those	operated	under	GA.	The	increased	
number	of	subtotal	resections	in	the	GA	group	may	contribute	to	the	reduced	rate	of	seizure	
freedom.		
When	comparing	seizure	outcome	in	patients	with	oligodendrogliomas	to	astrocytomas	based	on	
the	2016	WHO	update,	slightly	more	patients	with	oligodendrogliomas	were	Engel	class	I	(79%	and	
67%	respectively),	however	this	is	not	statistically	significant.	In	contrast,	Chang	et	al.	(8)	report	that	
patients	with	oligodendrogliomas	are	more	prone	to	seizures	due	to	a	tendency	to	be	located	
cortically.	It	was	generally	thought	that	more	cortically	located	tumours	are	more	prone	to	
developing	seizures,	which	included	the	no	longer	used	classification	of	oligoastrocytoma.	Where	
astrocytomas	were	thought	to	be	mainly	found	in	white	matter	tracts	they	were	thought	to	have	less	
seizures	apart	from	protoplasmic	astrocytomas	which	were	linked	to	chronic	epilepsy.		After	
reclassification,	tumour	type	did	not	have	an	impact	on	seizure	outcome	in	our	cohort.	There	is	
somewhat	mixed	data	assessing	outcomes	based	on	tumour	type.	Previous	studies	have	shown	both	
improved	outcome	with	certain	tumour	type	(oligodendroglioma;	(18)	or	no	difference	in	outcome	
(19).	Furthermore,	there	is	conflicted	evidence	that	oligodendrogliomas	are	more	likely	to	have	
seizures	as	a	presenting	symptom	(9,20)	but	in	our	cohort	tumour	type	did	not	predict	which	
patients	would	present	with	seizures	initially,	with	no	significant	difference	between	
oligodendrogliomas	and	astrocytomas	in	terms	of	seizures	as	a	presenting	symptom.	Additionally,	
although	oligodendrogliomas	had	more	indistinct	borders	than	astrocytomas	based	on	the	2016	
classification	(59%	vs	35%),	there	was	no	difference	in	EOR	or	seizure	outcome	in	this	series	,	which	
may	reflect	the	small	numbers	in	each	subgroup	and	requires	further	study.	
The	2016	WHO	update	has	not	shown	significant	changes	in	prognosis	in	our	series.	The	greatest	
difference	was	in	seizure	freedom	rates	of	oligodendrogliomas,	where	89%	were	Engel	class	I	post-
operatively	based	on	the	old	classification	system	compared	to	79%	after	reclassification.	This	may	
be	due	to	fact	that	the	majority	of	oligoastrocytomas,	which	had	the	highest	proportions	of	patients	
presenting	with	seizures	(89%)	and	lowest	proportion	Engel	class	I	post-operatively	(40%),	were	
reclassified	as	oligodendrogliomas	and	thus	reduced	the	rate	of	seizure	freedom.	Aside	from	this,	
there	was	very	little	impact	on	rates	of	tumour	recurrence	between	tumour	types	and	no	change	
between	rates	of	new	seizures.	Larger	long	term	case	series	will	be	required	to	demonstrate	
differences	in	clinical	features	and	outcome	after	the	2016	update.	
Delfanti	et	al.	aimed	to	correlate	imaging	characteristics	with	tumour	classification	based	on	the	
2016	update	in	a	retrospective	study	of	40	patients	(21).		They	identified	that	tumour	classification	
had	an	impact	on	tumour	location,	appearance	of	borders	on	MRI	and	progression	free	survival	
(PFS),	where	patients	with	no	IDH	mutation	had	significantly	shorter	PFS	(24).	It	may	be	that	tumour	
histology	under	the	new	classification	has	less	importance	to	seizure	outcome	compared	to	the	old	
system	but	has	a	greater	impact	in	relation	to	patient	demographics,	imaging	characteristics	and	
prognosis.		In	our	study,	pre-operative	radiological	variables	including	cortical	involvement,	mass	
effect,	eloquent	location,	border	distinction	and	tumour	signal	did	not	significantly	impact	on	seizure	
development,	outcome	or	the	ability	to	achieve	maximal	EOR.	Interestingly,	tumour	signal	
(homogenous	vs	heterogenous)	on	MRI	was	significantly	related	to	whether	seizures	were	the	
presenting	symptom,	which	may	reflect	as	yet	unknown	molecular	differences	within	tumours.	
IDH	mutation	status	has	previously	been	shown	to	be	associated	with	seizures	as	a	presenting	
symptom	and	increased	risk	of	future	malignant	transformation	(5,13,25–27).	However,	our	data	
showed	no	significant	correlation	between	IDH	mutations	and	seizures	as	a	presenting	symptom,	
seizure	outcome,	tumour	type	or	recurrence.	Therefore	the	use	of	IDH	mutation	status	alone	as	a	
prognostic	marker	was	limited	in	our	cohort.		
Tumour	volume	did	not	influence	seizure	outcome,	with	similar	mean	tumour	volumes	in	patients	
who	were	Engel	class	I	compared	to	class	II	or	above	post-operatively	(33.8	cm3	vs	30.3	cm3	
respectively).	However,	tumour	volume	did	influence	tumour	outcome,	as	cases	where	progression	
occurred	had	significantly	larger	initial	tumour	volumes	compared	to	those	which	did	not	(p=0.008;	
mean	volumes	44.2	cm3	vs	26.0	cm3	respectively).	This	is	likely	linked	to	the	potential	EOR	achievable	
with	larger	tumours,	as	mean	tumour	volume	was	significantly	greater	in	patients	who	underwent	
subtotal	resection	compared	to	those	who	had	near-total	or	complete	resection	(54.9	cm3	vs	23.8	
cm3;	p=<0.01).	Thus,	larger	initial	tumour	volumes	appear	to	reduce	the	possible	EOR,	which	has	also	
been	shown	elsewhere	(1).	We	did	not	identify	a	link	between	tumour	volume	and	seizures	as	a	
presenting	symptom	whereas	others	have	shown	that	larger	tumours	tended	to	present	with	
seizures	(28).		
For	patients	that	did	not	present	with	seizures,	it	is	not	obvious	as	to	what	specific	factors	predict	
the	absence	of	seizures	or	what	led	to	development	of	seizures	in	7	of	the	18	(39%)	as	our	data	show	
no	statistically	significant	predictors.	The	majority	of	patients	who	went	on	to	develop	seizures	had	
oligodendrogliomas	(86%)	which	correlates	with	some	that	oligodendrogliomas	tend	to	be	more	
cortical	and	are	more	prone	to	seizure	activity,	but	this	result	was	not	significant	and	there	is	mixed	
evidence	in	the	literature	(8,9,20).		Previous	studies	have	suggested	that	larger	tumours	are	
indicative	of	a	longer	period	of	silent	growth,	with	more	time	for	seizures	to	develop	(28).	It	is	
possible	that	more	patients	would	have	gone	on	to	develop	seizures	had	they	not	presented	with	
other	symptoms	or	as	an	incidental	finding.	Leading	on	from	this,	our	finding	that	tumour	volume	
was	significantly	smaller	in	tumours	located	in	eloquent	regions	compared	to	non-eloquent	regions	
(22.0	cm3	vs	37.7	cm3	)	is	most	likely	due	to	eloquently	located	tumours	producing	symptoms	at	an	
earlier	stage	in	their	growth.	
We	identified	several	key	factors	that	predict	tumour	recurrence,	in	line	with	recent	studies	(1,26).	
Evidence	of	mass	effect	on	pre-operative	MRI,	larger	tumour	volumes	and	reduced	EOR	all	
statistically	correlated	with	an	increased	likelihood	of	recurrence.	Mass	effect	may	play	a	role	by	
affecting	resection,	whereby	compression	of	nearby	structures	limits	the	achievable	EOR.	Tumour	
volume	and	EOR	appear	to	interlink	in	their	effect	on	tumour	recurrence,	whereby	larger	tumour	
volumes	correlate	directly	with	tumour	recurrence	and	also	reduced	EOR,	which	indirectly	correlates	
with	survival	as	reduced	EOR	is	associated	with	tumour	recurrence.	Similar	data	has	been	shown	in	
other	studies	in	that	EOR	is	reduced	in	larger	tumours	as	well	as	tumour	volume	being	an	
independent	prognostic	factor	for	tumour	recurrence	(1,29).	
Overall,	pre-operative	radiological	variables	did	not	predict	seizure	outcome	in	our	cohort,	with	
tumour	volume	the	only	variable	that	influences	EOR	and	hence	seizure	outcome.	Even	tumour	
location	in	an	eloquent	region	does	not	influence	EOR	so	it	seems	that	with	judicious	use	of	awake	
craniotomy	it	is	possible	to	achieve	significant	resection	and	lead	to	a	favourable	outcome.	Tumour	
volume	appears	to	be	an	important	variable	relating	to	factors	such	as	EOR	and	tumour	recurrence	
but	does	not	affect	seizure	outcome.		In	this	study,	the	majority	of	patients	achieved	seizure	
freedom	and	thus	were	able	to	return	to	driving,	which	is	a	considerable	benefit	to	quality	of	life,	
particularly	due	to	the	young	age	and	previous	good	health	of	the	majority	of	LGG	patients.		
This	study	has	several	limitations	including	the	retrospective	analysis	of	a	single	institution	series.		
With	multiple	variables	it	is	possible	that	the	lack	of	statistical	significance	is	related	to	small	sample	
size.		However,	our	findings	regarding	EOR	and	outcome	are	in	line	with	the	current	LGG	literature	
and	further	larger	multicentre	studies	of	radiological	and	molecular	genetic	variables	are	required.		
5.  Conclusion 
Our	data	are	consistent	with	similar	studies	when	assessing	seizure	outcome	after	resection	of	LGG,	
in	that	a	greater	EOR	gives	improved	seizure	freedom.	Even	when	EOR	was	subtotal,	most	patients	
were	still	Engel	class	I,	indicating	that	the	newer	strategy	of	earlier	and	more	aggressive	resection	
may	result	in	a	better	overall	prognosis	for	patients	with	LGGs	and	improve	quality	of	life	with	
regards	to	seizure	freedom.	Radiological	variables	did	not	impact	seizure	outcome,	indicating	that	
cautious	resection,	particularly	with	the	use	of	intra-operative	functional	mapping,	is	still	possible	in	
the	majority	of	tumours	even	when	eloquently	located.	Regardless	of	pre-operative	variables,	it	
appears	the	most	important	predictor	of	seizure	outcome	is	maximal	safe	resection,	regardless	of	
tumour	type.	
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